GCTK Glucotrack, Inc.
Price Chart
Executive Summary
Glucotrack reported Q1 2026 results with a net loss of $4.3M, narrower than the $6.8M loss in Q1 2025, driven by a non-cash reduction in derivative liabilities. The key catalyst is the submission of its IDE application to the FDA for its implantable CBGM technology, targeting a U.S. clinical trial launch in 2H 2026. Cash runway extends into early Q3 2026, providing a narrow window before the next capital need.
Actionable Insight
The IDE submission is a binary catalyst — FDA acceptance could drive a significant re-rating, while rejection or clinical delays would accelerate the cash crunch. With only ~$3.9M cash and a $1M ELOC draw post-quarter, the company likely needs additional financing within 3-6 months. Monitor for FDA feedback on the IDE and any capital raise announcements.
Key Facts
- Net loss for Q1 2026 was $4.3M vs $6.8M in Q1 2025, a $2.5M improvement primarily from a non-cash change in derivative liabilities
- Cash and cash equivalents were $3.9M as of March 31, 2026, down from $7.4M at December 31, 2025
- Company submitted IDE application to FDA for its fully implantable CBGM technology
- Promissory note balance reduced from $3.6M to approximately $1.6M via stock-for-debt exchange
- Subsequent to quarter end, drew ~$1.0M under existing equity line of credit facility
- Shares outstanding increased from 910,688 at Dec 31, 2025 to 2,524,279 at March 31, 2026
- Cash runway expected into early Q3 2026, sufficient to initiate U.S. clinical trial
Financial Impact
Net loss improved by $2.5M YoY to $4.3M; cash burn of $4.1M from operations in Q1 2026
Risk Factors
- Cash runway only into early Q3 2026 — high risk of dilutive financing before clinical trial initiation
- IDE may not be approved by FDA, delaying or derailing U.S. clinical trial plans
- Share count more than doubled in Q1 2026 (910K to 2.5M shares), with further dilution from ELOC draws and warrant exercises likely
- Pre-revenue development-stage company with no approved products and history of operating losses
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023202 |
| Document: form8-k.htm | 0001493152-26-023202 |
| Document: 0001493152-26-023202-index-headers.html | 0001493152-26-023202 |
| Document: 0001493152-26-023202-index.html | 0001493152-26-023202 |
| Document: 0001493152-26-023202.txt | 0001493152-26-023202 |
| 8-K Data (Synthetic) | 0001493152-26-023202 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
8d ago
|
8-K
| — | awaiting T+5 | — | — |
|
May 14, 2026
9d ago
|
8-K
| $0.6655 awaiting T+5 | awaiting T+5 | — | $0.5000 (−24.87%) |
|
May 7, 2026
16d ago
|
Press Release
| $0.8600 $0.7000 | ▼ −18.60% | ▼ −20.11% | $0.5000 (−41.86%) |
|
Apr 30, 2026
23d ago
|
8-K
| $0.8000 $0.8600 | ▼ −7.50% | ▼ −5.15% | $0.5000 (+37.50%) |
|
Apr 14, 2026
5w ago
|
8-K
| $0.7350 $0.7490 | ▼ −1.90% | ▼ −0.51% | $0.5000 (+31.97%) |
|
Mar 30, 2026
7w ago
|
8-K
| $0.6500 $0.6830 | ▲ +5.08% | ▲ +1.13% | $0.5000 (−23.08%) |
|
Mar 30, 2026
7w ago
|
Press Release
| $0.6500 $0.6830 | ▲ +5.08% | ▲ +1.13% | $0.5000 (−23.08%) |
|
Mar 27, 2026
8w ago
|
Press Release
| $0.9900 $0.8300 | ▼ −16.16% | ▼ −20.02% | $0.5000 (−49.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access